A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 As Adjunctive Treatment for Major Depressive Disorder (MDD)

Study Overview This clinical trial is a Phase 3 research study designed to test the safety and effectiveness of an investigational drug called REL-1017 (esmethadone HCl). The goal is to determine if REL-1017 can help people with major depressive disorder (MDD) who are already taking other antidepressant medications but have not experienced enough improvement.
Why This Study Is Important MDD is a serious condition that affects mood, cognition, motivation, energy, and daily life. Some people do not respond fully to standard antidepressants. REL-1017 is being tested as an additional treatment to see if it can improve symptoms more effectively.
Who Can Participate The study is enrolling adults diagnosed with major depressive disorder who do not have enough relief from their current antidepressant medications. Specific criteria must be met to join the study.
What Happens in the Study Participants will be randomly assigned to receive either REL-1017 or a placebo (an inactive substance) along with their current antidepressant. This process helps researchers understand the effects of the drug. Neither the participants nor the researchers will know who receives REL-1017 or the placebo during the study.
Study Details Duration: The study involves several weeks of treatment and follow-up visits. Assessments: Participants will complete health evaluations, including physical exams and questionnaires, to monitor progress and side effects.
Costs: Study-related treatments and assessments are provided at no cost to participants.
Potential Benefits and Risks Benefits: Participants may experience improvements in depressive symptoms. Risks: As with any investigational medication, there may be side effects. All participants will be closely monitored by the study team.

开始日期2024-12-27

申办/合作机构-

NCT06011577

/ Terminated临床3期

A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)

A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).

开始日期2023-08-17

申办/合作机构

Relmada Therapeutics, Inc.

NCT04145674

/ Recruiting临床2期IIT

A Proof of Concept, Multicentre, Phase 2, Double-Blind, Randomized, Placebo-Controlled Study on the Efficacy, Safety and Tolerability of d-Methadone in Moderate to Very Severe Restless Legs Syndrome With Periodic Limb Movements: the Glu-REST Study

Proof of concept, double-blind, randomized, placebo-controlled trial with d-methadone proposed for the first time for use in the treatment of patients diagnosed with primary, moderate to very severe Restless Legs Syndrome (RLS). Its glutamatergic mechanism of action might be effective on RLS arousal pattern and sleep disturbance which highly impair the quality of life of RLS's patients.
Patients will take the study drug/placebo once a day for 30 consecutive days.

开始日期2022-10-22

申办/合作机构

Ente Ospedaliero Cantonale

100 项与右美沙酮相关的临床结果

登录后查看更多信息

100 项与右美沙酮相关的转化医学

登录后查看更多信息

100 项与右美沙酮相关的专利（医药）

登录后查看更多信息

410

项与右美沙酮相关的文献（医药）

2025-10-01·PHARMACOLOGICAL RESEARCH

All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants

Review

作者: Freudenberg, Florian ; Reif, Andreas ; McKernan, Ruth M ; Dawson, Gerard R ; Reif-Leonhard, Christine

Treatment-resistant depression (TRD) represents a major clinical challenge. Affecting about 30 % of major depressive disorder (MDD) patients, effective treatments for TRD are urgently needed. While depression research and antidepressant (AD) development have long centred on monoaminergic targets, research over the past 35 years has increasingly explored glutamatergic mechanisms. Here we present an extended discussion on developments in glutamatergic drug discovery, focusing on mechanistic convergence between NMDA and AMPA receptor signalling. Beyond established rapid-acting antidepressants (RAADs), such as (es)ketamine and dextromethorphan/bupropion (AXS-05), we highlight novel therapeutic directions involving esmethadone (REL-1017), nitrous oxide, and positive allosteric modulators (PAMs) of NMDA receptors (e.g. rapastinel, zelquistinel, and apimostinel). Moreover, we discuss forward-looking strategies using AMPA receptor PAMs (e.g. osavampator and tulrampator) and targeting of AMPA receptor-interacting proteins. By integrating recent clinical evidence with molecular and physiological findings, we highlight a convergent mechanism across these compounds. This involves increased AMPA receptor activation, triggering BDNF release and mTOR signalling, promoting synaptic strengthening through enhanced AMPA receptor trafficking and dendritic spine formation. Together, targeting glutamatergic signalling represents a transformative path for TRD treatment with high efficacy by more directly modulating pathologically affected signalling modules. These developments place glutamatergic agents at the forefront of next-generation AD strategies.

2025-09-01·EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression

Review

作者: Reif, Andreas ; Freudenberg, Florian ; Reif-Leonhard, Christine

Abstract:

Changes in glutamatergic neuroplasticity has been proposed as one of the core mechanisms underlying the pathophysiology of depression. In consequence components of the glutamatergic synapse have been explored as potential targets for antidepressant treatment. The rapid antidepressant effect of the NMDA receptor antagonist ketamine and subsequent approval of its S-enantiomer (i.e. esketamine), have set the precedent for investigation into other glutamatergic rapid acting antidepressants (RAADs). In this review, we discuss the potential of the different glutamatergic targets for antidepressant treatment. We describe important clinical outcomes of several key molecules targeting components of the glutamatergic synapse and their applicability as RAADs. Specifically, here we focus on substances beyond (es)ketamine, for which meaningful data from clinical trials are available, including arketamine, esmethadone, nitrous oxide and other glutamate receptor modulators. Molecules only successful in preclinical settings and case reports/series are only marginally discussed. With this review, we aim underscore the critical role of glutamatergic modulation in advancing antidepressant therapy, thereby possibly enhancing clinical outcomes but also to reducing the burden of depression through faster therapeutic effects.

2025-09-01·PHARMACOLOGICAL RESEARCH

Distinctive biochemical properties of the μ-opioid receptor-corticotropin- releasing factor CRF1 receptor heterotetramer

Article

作者: Casadó, Vicent ; Cai, Ning-Sheng ; Casajuana-Martín, Nil ; Sanchez, William N ; Ferré, Sergi ; Ciruela-Jardí, Marc ; Pardo, Leonardo ; Yauch, Anne ; Plant, Leigh D ; Quiroz, Cesar ; Chang, Ya Gin ; Moreno, Estefanía

Heteromerization of Gs with Gi protein-coupled receptors has been suggested to be necessary to sustain the canonical Gi-Gs antagonistic interaction at adenylyl cyclase (AC). These heteromers have a tetrameric quaternary structure, composed by two homodimers each one coupled to its corresponding G protein. We describe the heterotetramer formed by the Gi-coupled μ-opioid receptor (MOR) and the Gs-coupled corticotropin releasing factor CRF₁ receptor (CRF₁R), which also sustains a canonical interaction at AC and reciprocal allosteric interactions between MOR and CRF₁R ligands. In addition, we found that CRF₁R can also couple to Gq proteins in the MOR-CRF₁R heteromer, providing the frame for also canonical Gi-Gq antagonistic interactions that include other effectors, such as phospholipase C and its Ca^2 + -dependent signaling, and which control glutamate release in the central amygdala (CeA). The specific pharmacodynamic properties of the MOR-CRF₁R heteromer, including its sensitivity to S-methadone, as well as its localization in the CeA suggest it might represent a significant pharmacological target for the analgesic, antistressor and antidepressant effects of opioids and the hyperalgesia of opioid withdrawal.

102

项与右美沙酮相关的新闻（医药）

2025-07-16

·药时代

被安慰剂“做了局”？又一款CNS药物倒下了

全文共2800字预计阅读时间：7分钟近期，Relmada Therapeutics向美国证券交易委员会（SEC）提交的文件中宣布已停止其在研NMDA 受体拮抗剂艾司美沙酮（esmethadone）的开发工作，为该药物资产充满挑战的研发历程画上了句号。谁能想到，就在几年前，这款药物还曾凭借抑郁症II期临床的亮眼数据风光一时，直接引爆公司股价狂飙134%，堪称CNS领域的一匹黑马。一波三折的临床研究灾难始于2022年10月13日这天，一则REL-1017 在RELIANCE三期临床失败的公告在Relmada官网上发布，直接令股价“踝斩”，单日下跌近80%。试验结果表明，REL-1017单药治疗抑郁症未能达到「抑郁症症状评分改善」的主要终点。药物组与安慰剂组之间的差异过小，并未达到统计学显著水平。简单说就是：REL-1017疗效没比安慰剂强太多，甚至还被超越了。第二次失败在2个月后接踵而至。REL-1017作为辅助治疗在另一项III期研究 RELIANCE-I 中同样未能达到主要终点，抑郁症症状没有得到显著改善。凭借2次安慰剂的“逆袭”，Relmada直接入选了2022年度烂番茄公司，对此管理层公开表示不服气，称这全是“安慰剂“的锅，安慰剂组数据不可信的。为此，Relmada进行了事后分析：删除了他们认为有问题的安慰剂患者数据，表示REL-1017在统计上仍然具有显着优势。这就像是考生拿到批改后的试卷，觉得老师打分不公，干脆自己拿起红笔，把“冤枉扣的分”又加回到了卷面总分上。大家当然更不买Relmada的账了。第三次还没揭盲，就被宣告“死亡“。独立数据监测委员会（DMC）对REL-1017的III 期研究RELIANCE-II 进行中期分析后得出结论：该研究成功的可能性极低，几乎可以判定为“无效”。随后，Relmada宣布终止REL-1017的III 期 Reliance II 研究和III期RELIGHT研究。如今这家成立超20年，团队成员有数十年药物开发经验，管理层来自多家跨国大药企的明星biotech公司，遭受了核心管线艾司美沙酮黯然退出的打击。它还曾将希望寄托于裸盖菇素（迷幻药）在肥胖症中的应用，结果红海竞争汹涌而来，把它直接“拍死在岸上”，宣告管线暂停。如今，Relmada手里只剩下两条管线：NDV-01和Sepranolone顽强挣扎。只能说：祝它成功吧！安慰剂也能治病？在二战期间，意大利战区的一个临时战地医院里，美国军医Henry K. Beecher正面临一场生死攸关的抉择。手术台上躺着一名重伤士兵，炮弹碎片撕裂了他的腹部，疼痛让他几近昏厥。可就在这时，最后一支镇痛剂已经用完了。Beecher颤抖着手，将一瓶生理盐水推进了士兵的静脉。他不敢看病人的眼睛，只希望这个“谎言”能撑过接下来的折磨。然而，奇迹发生了——士兵脸上的痛苦表情逐渐缓和，而且手术时也没有感受到剧烈的疼痛。那一刻，Beecher意识到：止痛的，或许不是药物本身，而是士兵坚信自己已被治疗的信念。这个发现，悄然埋下了现代医学对安慰剂效应研究的种子。1955年，Beecher在《美国医学会杂志》（JAMA）上发表了具有里程碑意义的论文《The Powerful Placebo（安慰剂的力量）》。首次系统性指出：吃药这个行为，本身就是一种治疗。即使成分并无特殊功效，但因为期望，往往带来身体和情绪的好转。当患者相信自己正在接受有效治疗时，就会产生一种积极的心理预期：“我正在接受治疗，我的病会好起来。”这种信念能够激活大脑中的内源性奖赏系统，促使神经递质如内啡肽、多巴胺等被释放出来，这些被称为“快乐分子”的物质，有助于改善情绪、缓解焦虑，甚至减轻疼痛。换句话说，安慰剂并非真的“无效”或“空无一物”，它只是没有“姓名”，却拥有实实在在的“脑内自产”效果。患者确实感觉好了，但对药企来说，这却是个大烦恼：怎么证明你的药真的有效呢？尤其是在抑郁症等中枢神经系统（CNS）疾病领域，缺乏客观生物标志物、高度依赖患者主观报告的情况下，安慰剂就像一个“隐形竞争者”，悄无声息地搅局，影响试验结果的判断。它不光是心理作用，更是一道横亘在新药审批路上的“统计学门槛”。当我们在问“这个药到底有没有效”的时候，也许更该问一句：“我们的大脑，是不是已经悄悄地帮了一把？”如何打破“安慰剂诅咒”但在这之前，谁来帮帮这些陷入“绝望”的药企？今年年初，药时代曾报道了一篇引发行业共鸣的文章：《安慰剂“杀疯”了？CNS研发药企众生相》，一场突如其来的“黑色星期一”打得CNS药企措手不及。Biohaven、Neumora和Lexicon三家药企在同一天宣布：其候选药物在关键临床试验中，未能在所有剂量组中显著优于安慰剂，导致试验失败。实际上，这样的困境并非个例。近年来，多家大型制药公，例如罗氏、默沙东、葛兰素史克（GSK）、阿斯利康等巨头也相继收缩或完全退出了CNS领域的研究，转向更为确定的治疗领域如肿瘤学和免疫学。那么，我们该如何应对安慰剂效应对CNS疾病临床研究带来的影响？识别与疾病发生和发展密切相关的靶点与生物标志物（Biomarkers）：客观生物标志物的应用是提升CNS临床试验科学性和可靠性的关键进展之一，可以更准确地衡量治疗效果，减少主观偏差和安慰剂效应的影响。在抑郁症的临床试验中，经颅磁刺激（TMS）与脑电图（EEG）的联合应用不仅能够在刺激脑组织的同时实时采集脑电信号，还可对大脑皮质的电生理变化进行量化评估，从而更准确地反映神经调控效应，显著降低安慰剂效应的干扰。多模态数据整合：这被视为CNS临床试验的重要方向，通过结合脑成像、电生理记录、生物标志物及临床症状评估等多种手段，构建全面的疗效评价体系。这就如同评估学生不再仅依赖考试成绩，而是从德、智、体、美、劳多维度考察，更准确反映其真实素养。精选受试者人群以降低易受暗示性：还有一种“简单粗暴但有效”的策略，直接筛选掉易受心理暗示的人群。通过科学的筛选标准，例如心理量表评估，可以有效识别并排除对治疗易产生暗示反应的患者，从而降低安慰剂效应在临床试验中带来的干扰。例如，明尼苏达多项人格测验（MMPI）中的效度量表（如诈病量表F），就可检测被试者是否存在夸大症状报告的行为。结语在CNS疾病这片机制复杂且难以捉摸的“暗黑森林”中，单纯依赖传统量表评分和剂量递增的药物开发模式已暴露出诸多局限与风险。要突破当前困局，亟需探索更为高效、稳定的新型临床试验方案，以科学手段破解安慰剂效应带来的“诅咒”，推动CNS领域研发走向更精准、可预测的新阶段。参考资料：1.https://www.biospace.com/drug-development/after-three-strikes-relmada-abandons-depression-drug-esmethadone2.股价单日暴跌近80%！唯一进临床的管线三期试验失败，原因竟是安慰剂效果太好...（药时代）3.安慰剂“杀疯”了？CNS研发药企众生相（药时代）4.公开披露信息图片来源：《暖暖内含光》电影图超越输血与EPO：东阳光药HEC53856将重塑化疗性贫血治疗格局2025-07-15高盛：创新药的好行情才刚起步......2025-07-14谈笑风生！上任100天！FDA新掌门Makary局长（马局长）发文总结 | 视频+直播2025-07-14版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn点击这里，查看更多资讯！

临床3期临床2期

2025-07-16

·生物制药小编

效果不如安慰剂，公司选择退货

在经历了三次的临床失败之后，Relmada Therapeutics最终放弃了其引进REL-1017的开发权益。这项授权协议最早是在2018年1月签订，授权方是康奈尔大学的两位医学博士Charles Inturrisi、Paolo Manfredi。价格相当便宜，首付款只有18万美元，不过，这个授权协议特殊的一点在于—该授权交易的后续付款，即，Relmada需每三个月向Inturrisi和Manfredi支付4.5万美元，直到REL-1017上市销售或专利到期为止。现在，REL-1017实现获批上市销售不可能达到了，Relmada再不选择终止协议，就等于白白送钱了。安慰剂效果太好？REL-1017是一款NMDA受体通道阻断剂，旨在优先靶向过度活跃的GluN1-GluN2D NMDAR通道，阻止过量钙离子进入神经元内，同时维持生理性谷氨酸能神经传递，恢复神经元回路。作为唯一一条管线，REL-1017曾备受Relmada倚重。2019年10月，REL-1017治疗重度抑郁症的II期临床大获成功，使公司股价大涨了134%，因此备受关注。然而，REL-1017进入III期临床后不断失利。2022年10月， Relmada宣布，REL-1017作为重度抑郁症（MDD）单药治疗的III期临床RELIANCE III未能达到主要终点，相比安慰剂，REL-1017的MADRS10评分未能达到显著改善（-14.8分 vs -13.9分）。这一消息令投资者对此十分失望，受此消息影响，当日公司股价暴跌近78%。然而，打击接踵而至，两个月后，Relmada就再次报告了REL-1017临床失败的消息。2022年12月，Relmada宣布，REL-1017作为重度抑郁症（MDD）辅助治疗的III期RELIANCE-I也未能达到试验主要终点。相比慰剂组，REL-1017组患者的MADRS评分没有得到显著改善（-15.1分 vs -12.9分），公司股价跌去40%。并且更不好的信号是，RELIANCE-III和RELIANCE-I的某些试验站点都出现了安慰剂的效果显著优于REL-1017的情况。除了临床令人所望之外，Relmada关于该项临床失败的事后解释也让外界对其观感变差。关于两项临床失败，Relmada将其解释为“安慰剂效果太好”，因此，Relmada还进行了一个事后分析：专门剔除了安慰剂组过高或过低的数据，使得REL-1017组的MADRS评分相比安慰剂组达到了显著差异。即便如此，也还是没能扭转REL-1017的命运。到2024年12月，经独立数据监测委员会（DMC）分析，认为其RELIANCE II试验不太可能达到主要终点。这一结论令Relmada彻底失去希望，随即，Relmada终止了该项临床试验，并连同另一项临床方案相似的临床试验RELIGHT。同步的，Relmada宣布了寻求其他战略方案，包括合并或出售公司。用迷幻药来减肥？除了对REL-1017临床失败进行强行解释之外，Relmada还有一些迷惑操作。或许是为了防止对REL-1017的过度依赖。在2021年，Relmada从Arbormentis公司引进了其裸盖菇素及其衍生物项目（REL-P11）的开发和商业化权利，首付款1500万美元（现金+股权），潜在里程碑付款约为1.5亿美元。裸盖菇素，因为被发现在抑郁症和焦虑症的治疗中具有明显疗效，近年来，重点被开发用于精神疾病治疗。但这家公司不走寻常路，将REL-P11（低剂量缓释型裸盖菇素）开发用于治疗肥胖症在内的代谢性疾病。Relmada还成功的将其推进到临床Ⅰ期阶段。但现在已经被暂停开发了。在公司2024的财报中，REL-P11就被列为重新评估对象，目前，已经被暂停开发了。原因是认为减肥领域竞争太激烈，以及迷幻药监管批准较为严格等。目前，Relmada的战略重心是剩下的两条管线NDV-01和Sepranolone。NDV-01是一种吉西他滨和多西他赛复方缓释制剂，用于治疗非肌层浸润性膀胱癌（NMIBC），目前处于临床Ⅱ期阶段。Sepranolone是一种GABA-A调节类固醇拮抗剂，2025年2月从Asarina Pharma获得许可，目前处于临床Ⅱb期阶段。就现金情况看来，现在要推进这两条管线的开发也相当具有挑战性。据该公司2025年一季度财报，截止2025年3月31日，公司现金、现金等价物和短期投资约为2710万美元。参考出处：https://www.relmada.com/for-investors/news/detail/318/relmada-therapeutics-reports-first-quarter-2025-financialhttps://www.fiercebiotech.com/biotech/relmada-terminates-license-agreement-troubled-phase-3-depression-assethttps://www.sec.gov/Archives/edgar/data/1553643/000121390018000707/f8k011618ex10-1_relmada.htmhttps://www.fiercebiotech.com/biotech/relmada-reconsiders-plans-test-magic-mushroom-extract-obesity#:~:text=At%20the%20time,as%20part%20of%20our%20prioritization%20efforts

临床3期引进/卖出临床2期临床失败临床结果

2025-07-14

·BioSpace

After Three Strikes, Relmada Abandons Depression Drug Esmethadone

iStock, Wel_nofri The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage trials. Relmada Therapeutics has halted development of its investigational NMDA receptor blocker esmethadone, ending what has been a rough journey for the asset. The company made the announcement in an SEC filing on Friday. The company said that it will terminate a January 2018 licensing agreement , under which it obtained global rights to esmethadone. The molecule was originally deveoped by Charles Inturrisi, a professor at Weill Cornell Medical. Inturrisi then himself licensed it to Medeor, co-founded Paolo Manfredi. Medeor merged with Relmada in 2013. As per the terms of the original contract, Relmada paid a nonrefundable sum of $180,000 upfront to Inturrisi and Manfredi, plus $45,000 every three months ever since. Those quarterly payments were intended to continue until certain conditions were met, including the first market sale of esmethadone or the expiration of its patent. None of such events occurred over the course of the partnership. Esmethadone’s development history has been fraught for some time now. In October 2022, the drug asset failed the Phase III RELIANCE III trial in major depressive disorder (MDD), unable to significantly ease the severity of depressive symptoms as a monotherapy versus placebo. Esmethadone delivered another late-stage disappointment in December of the same year, when the drug again showed no significant benefit in the RELIANCE I study, this time as an adjunctive MDD treatment. For both RELIANCE I and RELIANCE III trials, Relmada blamed an “unplausible placebo response” for the lack of significant efficacy signals for esmethadone. Then, in December 2024, the Phase III RELIANCE II also ended in failure , with an interim analysis finding a high likelihood of futility. A couple of weeks later, Relmada discontinued RELIANCE II and the Phase III RELIGHT study, also in MDD. With esmethadone now gone from its pipeline, Relmada has “made the exploration of strategic product acquisitions our primary focus,” according to a note to investors on its website . The company is focusing its efforts on NDV-01, a Phase II proprietary sustained-release formulation of gemcitabine and docetaxel being trialed for non-muscle invasive bladder cancer. Relmada licensed NDV-01 from Trigone Pharma in March. Phase II data presented in April showed an 85% three-month overall response rate . Relmada is the latest biotech to stumble in the difficult depression space. Last month, for example, Alto Neuroscience’s ALTO-203 was unable to significantly boost mood in patients with MDD in a Phase II study, forcing the California company to dig into exploratory endpoints and look at EEG biomarkers for signals of efficacy. In February, Supernus Pharmaceuticals likewise had a mid-stage stumble when its asset SPN-820 failed to improve symptom burden in patients with treatment-resistant depression. Even Big Pharma seems to have been having trouble making headway into depression, with Johnson & Johnson in March discontinuing the late-stage VENTURA program after its kappa opioid receptor blocker aticaprant failed to demonstrate sufficient efficacy signals to support continued development.

临床2期临床3期引进/卖出临床结果临床失败

100 项与右美沙酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	右美沙酮	-	DB15198

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重度抑郁症	临床3期	美国	Relmada Therapeutics, Inc.	2021-01-08
难治性抑郁症	临床2期	美国	Relmada Therapeutics, Inc.	2018-05-11
神经痛	临床1期	-	Relmada Therapeutics, Inc.	2014-12-04
Rett综合征	临床前	美国	Relmada Therapeutics, Inc.	2019-02-20
肌萎缩侧索硬化	临床前	美国	Relmada Therapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04855760 (Pubmed \| J Clin Psychiatry)	临床3期	重度抑郁症	624	Esmethadone	齋範築積獵簾選鑰鑰顧(糧窪艱廠獵鑰鏇憲構簾) = 2.6% 製願構餘選構鬱窪獵糧 (襯鏇顧淵衊鑰構遞觸廠 ) 更多	积极	2025-02-17
NCT04855747 (Reliance II, GlobeNewswire) 人工标引	临床3期	重度抑郁症	-	REL-1017	獵鏇鏇觸蓋構築糧選遞(觸製構蓋鹽醖衊憲鏇夢) = futile and is unlikely to meet the primary efficacy endpoint. 積鹹遞淵鏇醖壓糧鹽鑰 (鹹鏇選鬱壓艱夢憲構積 ) 未达到更多	不佳	2024-12-04
NCT04855760 (RELIANCE-OLS, CTgov)	临床3期	重度抑郁症	627	REL-1017	構壓襯壓選願餘窪繭壓 = 顧淵壓齋鹽鹽憲膚積淵艱鬱窪鏇夢蓋膚遞廠憲 (糧顧襯窪願簾顧淵齋繭, 蓋製夢獵憲願繭醖範獵 ~ 鬱鏇顧蓋簾積積鹽築鬱) 更多	-	2024-08-09
NCT04688164 (Psychiatry) 人工标引	临床3期	重度抑郁症	227	REL-1017	繭糧窪鑰繭鬱鬱製衊糧(醖選淵範衊憲廠膚廠艱) = 遞簾衊構餘鏇製構醖艱製積鏇顧壓鹹願廠遞網 (艱遞簾壓夢鑰選鹹淵簾, 11.3) 更多	不佳	2024-06-17
				Placebo	繭糧窪鑰繭鬱鬱製衊糧(醖選淵範衊憲廠膚廠艱) = 壓鑰鬱積繭齋選顧鏇鏇製積鏇顧壓鹹願廠遞網 (艱遞簾壓夢鑰選鹹淵簾, 10.4) 更多
NCT03051256 (REL-1017, Pubmed)	临床2期	重度抑郁症	62	Esmethadone 25 mg	夢構範獵窪製簾願膚觸(鏇遞範願鬱願壓膚壓醖) = 膚簾糧觸齋鹽夢鏇鹹築網憲築艱觸壓糧廠遞衊 (醖糧顧襯鏇壓夢糧鏇鏇 ) 更多	积极	2024-05-13
				Esmethadone 50 mg	夢構範獵窪製簾願膚觸(鏇遞範願鬱願壓膚壓醖) = 蓋夢遞壓願製蓋鹽壓製網憲築艱觸壓糧廠遞衊 (醖糧顧襯鏇壓夢糧鏇鏇 ) 更多
NCT05081167 (RELIANCE III, CTgov)	临床3期	重度抑郁症	232	Placebo	鑰廠繭繭願鹹簾膚鏇鏇(衊積願願齋網鏇夢鑰選) = 憲膚構獵顧築觸窪齋廠願蓋壓廠鏇網顧積衊艱 (窪獵積願築壓壓壓鹽顧, 10.8) 更多	-	2024-03-26
NCT04855760 (RELIANCE-OLS, Biospace) 人工标引	临床3期	重度抑郁症	627	REL-1017	製廠鹽鹽簾積齋獵膚鹽(夢積齋繭艱鹹築淵積壓) = COVID-19 (9.7%), headache (9.7%), upper respiratory tract infection (8.6%), and nausea (5.0%). 鑰憲廠窪齋壓壓醖遞淵 (鑰齋鏇鬱壓憲窪獵簾繭 ) 更多	积极	2023-09-20
NCT05081167 (RELIANCE III, Corporate Publications) 人工标引	临床3期	重度抑郁症	232	REL-1017	鹽選餘遞遞憲醖憲網鏇(選選餘獵憲積膚顧膚襯) = 網廠鬱襯鑰窪廠積鏇憲艱遞艱積鑰齋遞齋網壓 (網蓋鬱壓淵膚齋觸鬱構 ) 未达到	不佳	2022-10-13
				Placebo	鹽選餘遞遞憲醖憲網鏇(選選餘獵憲積膚顧膚襯) = 齋淵網襯範襯襯餘願遞艱遞艱積鑰齋遞齋網壓 (網蓋鬱壓淵膚齋觸鬱構 ) 未达到
NCT03051256 (REL-1017, CTgov)	临床2期	重度抑郁症 \| 难治性抑郁症	62	REL-1017 (REL-1017 25 mg)	觸窪醖繭襯願獵壓鹹窪 = 餘願範憲鬱選艱窪蓋淵築膚糧鬱襯範製齋淵壓 (構選鑰夢顧淵遞鏇網鹹, 糧窪餘製襯廠醖獵壓觸 ~ 鬱鏇構艱積壓鹹顧衊簾) 更多	-	2021-03-17
				REL-1017 (REL-1017 50 mg)	觸窪醖繭襯願獵壓鹹窪 = 鏇鏇顧襯繭淵窪願遞膚築膚糧鬱襯範製齋淵壓 (構選鑰夢顧淵遞鏇網鹹, 齋選網夢積鏇範構顧鹽 ~ 鏇鹹選選餘顧壓範醖齋) 更多
NCT00588640 (CTgov)	临床1/2期	食管癌 \| 结肠癌 \| 乳腺癌 ... 更多	10	d-methadone (Phase I, Cohort l)	廠蓋獵齋淵艱鏇夢淵艱 = 艱鬱鏇廠鏇餘夢憲蓋蓋糧糧積餘衊衊襯製觸壓 (窪鬱獵繭鹽製鬱築築鹹, 憲衊鏇夢憲齋餘鏇築鹹 ~ 窪衊願鑰遞製鏇觸觸淵)	-	2016-08-10
				D-methadone (Patients Receiving D-methadone 40 mg)	鏇網壓願顧衊艱簾獵夢(築範憲願鹽積鑰窪廠艱) = 獵願鏇鑰築願醖繭遞鹽艱蓋範築夢膚襯齋夢蓋 (積範構淵構觸餘鑰齋顧, 觸簾壓製築餘顧製醖淵 ~ 糧簾糧齋淵蓋製艱餘願) 更多